Strategy
The BRAIN Biotech Group is strategically evolving into a product-focused company with an emphasis on specialty enzymes. The potential for new product development is based on our deep-rooted expertise in biotechnological solutions and more than thirty years of corporate development.
We continue to expand our product business through organic growth and value-enhancing acquisitions. In order to strengthen the BioProducts segment as the primary growth segment of the Group, we have invested in the expansion of production capacities at our sites in recent years.
Geographically, the BRAIN Biotech Group's growth strategy is focused on Europe and North America.
Targets & target achievement
Our mid-term goal is to establish the BRAIN Biotech Group among the top 10 specialty enzyme companies worldwide.
Since financial year 2021/22, we have been on a clear growth path again. We are aiming to double the Group's sales in the medium term - while at the same time increasing the adjusted EBITDA margin. In order to strengthen the BioProducts segment as the Group's primary growth segment, we have invested accordingly in the expansion of production capacities at our sites in recent years.
Our control concept
Our main financial control parameters include revenue growth and adjusted EBITDA. In the company’s view, revenue appropriately reflects the Group’s overall financial performance during the respective reporting period. Adjusted EBITDA better reflects the Group’s sustainable earnings trend than EBITDA, as it excludes exceptional items. Adjusted EBITDA is calculated by eliminating expenses from the share-based payments of BRAIN Biotech AG, as well as acquisition and integration costs from BRAIN Biotech Group’s expansion.
As financial performance indicators, the company refers to milestones reached in the context of cooperation agreements and option exercises. The number of milestones reached serves as an important measure of the technological targets achieved in the strategic industrial partnerships, and consequently of BRAIN Biotech’s technology expertise. The management metrics underlying the planning and steering are calculated based on International Financial Reporting Standards (IFRS).
Our sustainability concept
Our strategy for sustainable corporate development and our reporting follow established national and international guidelines. Our reporting is based on standards such as the German Sustainability Code, the UN Global Compact, the United Nations Sustainable Development Goals and the Global Reporting Initiative (GRI) and therefore meets the increased requirements for transparent sustainability reporting.
Sustainability at BRAIN Biotech Group
Innovation
Our ability to innovate is based on our expertise in microbiology, biotechnology, bioinformatics, natural compound chemistry and engineering, as well as our commitment to stay at the forefront of technology and methodology. Our R&D activities are not only the basis for our tailor-made creative solutions for our industrial customers. They are also the driving force behind the expansion of the Group's product portfolio with innovative new enzymes.
Portfolio actions
Product portfolio: In the past, we have expanded our enzyme portfolio in the food sector into adjacent market segments through acquisitions of enzyme companies. Further expansions are planned to continue the targeted growth path.
Product portfolio development projects: As part of a continuous portfolio management process, we strive to limit the risks of the research pipeline through our own development projects.
